Ultrasound contrast agent review suspended by federal court until FDA responds to citizen petitions.
This article was originally published in The Gray Sheet
Executive SummaryULTRASOUND IMAGING AGENT REVIEW BY FDA SUSPENDED until the agency responds to citizen petitions filed by Bracco Diagnostics, DuPont Merck and ImaRx, and Sonus, D.C. Federal Court Judge Paul Friedman rules April 21. The judge gave FDA until the end of June to respond to the citizen petitions.
You may also be interested in...
The International Generic and Biosimilar Medicines Association has urged the World Intellectual Property Organization to withdraw its support for a global database of pharmaceutical patent information. The Pat-INFORMED database – which is comprised of intellectual-property information provided by originators – contains unverified data and lacks appropriate safeguards, the IGBA contends.
Reforms to the US 180-day exclusivity incentive included in the Blocking Act that is part of the Lower Health Care Costs Act could cost the US healthcare system approximately $1.7bn, the AAM has warned.